Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy

Trial Profile

Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2015

At a glance

  • Drugs Vinorelbine (Primary)
  • Indications Advanced breast cancer; Bone metastases
  • Focus Therapeutic Use
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 28 Jun 2012 Planned end date changed from 18 Jun 2011 to 18 Mar 2012 as reported by European Clinical Trials Database record.
    • 16 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top